

2017 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

San Francisco, CA – March 11, 2017

Conference Location **DoubleTree Hotel San Francisco Airport - North** **Phone:** (415) 467-4400
5000 Sierra Point Parkway <http://www.doubletreesfo.com>
Brisbane, California, 94005

Parking at the Conference Complimentary Parking for all participants is included as part of the program.
Once you enter the self-parking area, bring the parking ticket to the Seminar Registration Desk

Driving Directions

- From San Francisco - Take U.S. 101 S to the Sierra Point Parkway exit. Exit Sierra Point Parkway. At the stop sign, go straight approximately one mile. The hotel is on the right.
- From Bay Bridge (East Bay) - Take 880 N to 80 Bay Bridge to 101 S. Exit at the Sierra Point Parkway. At the stop sign, go straight approximately one mile. The hotel is on the right.
- From 101 North - Take U.S. 101 S to the Sierra Point Parkway exit. Bear right onto Sierra Point Parkway S. Continue approximately one mile. The hotel is on the right.
- From 101 South - Take U.S. 101 N to the Sierra Point Parkway exit. Turn right. The hotel is on the right.
- From San Mateo Bridge (Oakland) - Take 880 S to 92 West, then to 101 N. Exit at the Sierra Point Parkway. The hotel is on the right

Seminar Agenda and Syllabus Information Registration and breakfast begin at **7:30 a.m.** in the **Ghirardelli Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00am	Welcome and Pre-Test
8:15 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Treatment of cirrhosis and hepatic encephalopathy • Management of esophageal varices • Treatment of ascites, edema and hepatorenal syndrome • Liver Transplantation, Listing Criteria and MELD Exceptions
9:05 am	Hepatocellular Carcinoma <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Chemotherapies
9:45 am	Hepatocellular Carcinoma: New Locoregional and Systemic Treatment Options <ul style="list-style-type: none"> • Current treatments with Sorafenib • New chemotherapy treatments in development
10:20 am	Break & View Exhibits
10:35 am	Primary Sclerosing Cholangitis (PBS)

	<ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
11:20 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	Lunch & View Exhibits
12:45 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
1:20 pm	NASH and LAL-D Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Obeticholic Acid • Elafibranor (GTR505)
2:00pm	<ul style="list-style-type: none"> • Break & View Exhibits
2:10 pm	Case Presentations: <ul style="list-style-type: none"> • HCC • PBC with inadequate response to Ursodiol • NASH Diagnosis and Treatment
2:50 pm	Post-test
3:10 pm	Adjourn

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is **received in writing no later than seven days prior** to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-16-878. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**Your Seminar
Faculty**



R. TODD FREDERICK, MD

Dr. Todd Frederick is a transplant Hepatologist with the San Francisco Center for Liver Disease at California Pacific Medical Center. He currently serves as Fellowship Director for Transplant Hepatology as well as the Director of Quality and Clinical Protocols for the Division.

Dr. Frederick was appointed by San Francisco Mayor Gavin Newsom to serve on the Hepatitis C Task Force in 2009 where he assisted in drafting recommendations to the City for an approach to the HCV epidemic.

Dr. Frederick is a member of several professional societies, including the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver.



NORAH TERRAULT, MD

Dr. Norah Terrault is the Professor of Medicine and Surgery and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored over 100 original articles, reviews and book chapters on viral hepatitis, and serves as the Deputy Editor for Liver Transplantation and Associate Editor for Hepatology.

Dr. Terrault is an investigator on several NIH-funded clinical studies in hepatitis B and C, and is an investigator on several ongoing clinical trials of antiviral therapies for patients with chronic Hepatitis B and C.



MARICE THOMAS, RFP

Marice is a Family Nurse Practitioner, Board Certified through American Nurses Credentialing Center. She graduated with Associate Degree in Nursing from College of the Redwoods in 1977, Bachelor's Degree in Nursing from CSU Dominguez Hills in 1987 and Master's Degree in Nursing- Family Nurse Practitioner from Sonoma State University in 1999.

Marice's initial practice area was in Primary Care with a focus on Family Practice. In 2005, she began an emphasis and training in Hepatology which was directed toward the treatment and management of Hepatitis C. This was in rural Northern California in association with Physician Foundation at California Pacific Medical Center.

Since 2007 a full time focus on Hepatology, Liver Transplant care, Advanced Hepatitis B and C, Liver Cancer care, Fatty Liver and all aspects of liver disease continues. Marice works in collaboration with Hepatologists and other providers at Sutter Pacific Medical Foundation and California Pacific Medical Center Liver Transplant Program.
